MarketPR
EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21SHFSNasdaq grants Safe Harbor Financial extra 180 days to meet bid priceOct 21INDPIndaptus Therapeutics completes $24 million private placementOct 21JEFJefferies discloses recent share repurchases at investor meetingOct 20LNZALanzaTech Global Files 8-K for LanzaJet Recapitalization and $10M Note IssuanceOct 20SJTSan Juan Basin Royalty Trust skips October distribution due to cost deficitOct 20EARNINGSAmy Schumer posts Caribbean vacation photos after weight-loss updateOct 20EARNINGSSpaceX Q3 revenue jumps 161% to $14.6 billionOct 20WORLDNew US medium-lift rockets emerge 13 years after Antares debutOct 20EARNINGSNextDC shares plunge 39.5% after slashing earnings forecastOct 21NLYAnnaly Capital Management reports $0.80 EAD per share for third quarterOct 21SHFSNasdaq grants Safe Harbor Financial extra 180 days to meet bid priceOct 21INDPIndaptus Therapeutics completes $24 million private placementOct 21JEFJefferies discloses recent share repurchases at investor meetingOct 20LNZALanzaTech Global Files 8-K for LanzaJet Recapitalization and $10M Note IssuanceOct 20SJTSan Juan Basin Royalty Trust skips October distribution due to cost deficitOct 20EARNINGSAmy Schumer posts Caribbean vacation photos after weight-loss updateOct 20EARNINGSSpaceX Q3 revenue jumps 161% to $14.6 billionOct 20WORLDNew US medium-lift rockets emerge 13 years after Antares debutOct 20
NewsMacro

Cebranopadol Heads to Greater China as Adneuris Therapeutics Licenses Pain Compound to Zhejiang Conba Pharmaceutical

An exclusive licensing agreement for cebranopadol, the pain treatment in development at Adneuris Therapeutics, places Zhejiang Conba Pharmaceutical at the center of the compound's Greater China effort. Conba takes on full development and commercialization rights across mainland China, Hong Kong, Macao, and Taiwan. Adneuris framed the deal as an important step toward realizing what it described as the global potential of cebranopadol.

By Grant HalloranMacro DeskJuly 14, 20262 min read
Share

Key takeaways

  • Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical an exclusive license to develop and commercialize the pain compound cebranopadol across Greater China.
  • The license covers all four Greater China territories: mainland China, Hong Kong, Macao, and Taiwan.
  • Conba holds full development and commercialization rights for cebranopadol within the licensed zone, while Adneuris retains all rights outside Greater China.
  • The announcement disclosed no financial terms, milestone payments, or upfront figures.
  • Cebranopadol is being developed for a broadly defined pain indication, with no specific target patient population named for the Greater China program.

An exclusive licensing agreement for cebranopadol, the pain treatment in development at Adneuris Therapeutics, places Zhejiang Conba Pharmaceutical at the center of the compound's Greater China effort. Conba takes on full development and commercialization rights across mainland China, Hong Kong, Macao, and Taiwan. Adneuris framed the deal as an important step toward realizing what it described as the global potential of cebranopadol.

Scope and structure of the license

The license is exclusive, covering the pain indication across all four territories that make up Greater China: mainland China, Hong Kong, Macao, and Taiwan. Zhejiang Conba Pharmaceutical carries both the development program and the commercialization rights within that zone. No financial terms, milestone payments, or upfront figures appear in the announcement.

For Adneuris Therapeutics, the deal delegates Greater China development to Conba while the broader program remains active elsewhere. The exclusive structure gives Conba sole authority over cebranopadol development and commercialization within the licensed zone. Adneuris retains all rights outside Greater China.

The compound and its indication

Cebranopadol is being developed for pain. The indication as stated in the agreement is broad, which gives Conba latitude to build a development program across the full therapeutic area within the licensed territories rather than a narrower sub-type. Adneuris did not specify a target patient population or a tighter clinical focus for the Greater China program in the announcement.

What to watch

The agreement is now in place. The next confirmable step is Zhejiang Conba Pharmaceutical beginning regulatory or clinical activity for cebranopadol in any of the four covered territories. A study submission or regulatory filing in mainland China, Hong Kong, Macao, or Taiwan would be the first concrete signal that cebranopadol is advancing under Conba's direction.

About this story

Filed by the macro desk of MarketPR on July 14, 2026. Source: globenewswire.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Outstanding margin debt hits $1.5 trillion, a record high

Outstanding margin debt has reached $1.5 trillion, marking a new all-time high. This level of leverage represents the fourth time since 1997 that outstanding margin debt has surged by at least 65% over a short period. The previous three…

Grant Halloran2 min read
02Macro

Berkshire stock hits post-Buffett high as Bending Spoons stake gains

Berkshire Hathaway shares closed Friday at their highest level since Warren Buffett announced in May 2025 that he planned to step down as CEO at the end of that year. Class A shares (BRK.A) ended the session at $798,000, while Class B…

Grant Halloran2 min read
03Macro

Vanguard S&P 500 ETF offers 0.03% expense ratio for $1,000 investment

The Vanguard S&P 500 ETF (VOO) charges an expense ratio of 0.03%, a cost that amounts to $0.30 on a $1,000 investment. The fund, which holds approximately $1.7 trillion in assets, provides exposure to the S&P 500 index, a benchmark…

Grant Halloran2 min read

Frequently asked

What is cebranopadol being developed to treat?

Cebranopadol is being developed for pain, with a broadly stated indication that lets Conba build a program across the full therapeutic area rather than a narrower sub-type.

Which territories does the license cover?

The exclusive license covers the four territories of Greater China: mainland China, Hong Kong, Macao, and Taiwan.

How much is the deal worth?

The announcement did not disclose any financial terms, milestone payments, or upfront figures.

What rights does Adneuris keep?

Adneuris retains all rights to cebranopadol outside of Greater China while delegating development and commercialization within the licensed zone to Conba.

What would be the first sign the deal is progressing?

The first concrete signal would be Zhejiang Conba beginning regulatory or clinical activity, such as a study submission or regulatory filing, in any of the four covered territories.